Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 8/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | HBB | P68871 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27279357 | 0.91 | MAPT (0.44) | MAPTNPC1HTTSMN1; SMN2RAB9A | |
| SCHEMBL27279340 | 0.91 | MEN1 (0.42) | MAPTNPC1HTTSMN1; SMN2RAB9A | |
| SCHEMBL27279420 | 0.91 | MAPT (0.46) | MAPTNPC1HTTSMN1; SMN2RAB9A | |
| SCHEMBL27280970 | 0.89 | MAPT (0.49) | MAPTNPC1HTTSMN1; SMN2RAB9A | |
| SCHEMBL27279351 | 0.87 | MEN1 (0.39) | MAPTNPC1HTTSMN1; SMN2RAB9A | |
| SCHEMBL27279312 | 0.85 | MAPT (0.45) | MAPTNPC1HTTSMN1; SMN2RAB9A | |
| SCHEMBL27279317 | 0.85 | MAPT (0.45) | MAPTNPC1HTTSMN1; SMN2RAB9A | |
| SCHEMBL27279344 | 0.84 | MAPT (0.49) | MAPTNPC1HTTSMN1; SMN2RAB9A | |
| SCHEMBL27279339 | 0.84 | MAPT (0.43) | MAPTNPC1HTTSMN1; SMN2RAB9A | |
| SCHEMBL27279758 | 0.84 | MAPT (0.44) | MAPTNPC1HTTSMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209010-A1 | PRODRUGS OF AZO COMPOUNDS AND THEIR SALTS | AMNEAL PHARMACEUTICALS LLC | 2024-06-27 | — | — | US | disclosed |
| US-20240209010-A1 | PRODRUGS OF AZO COMPOUNDS AND THEIR SALTS | AMNEAL PHARMACEUTICALS LLC | 2024-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240209010-A1 | PRODRUGS OF AZO COMPOUNDS AND THEIR SALTS | CYP11B1, CYP2C19, CYP11B2 | MAPT 2300/4885NPC1 407/4885HTT 4456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.